Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage

被引:45
作者
Emoto, C. [1 ]
Murase, S. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Global Res & Dev, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 47102393, Japan
关键词
cytochrome P450 (CYP); contribution; prediction; relative activity factor; in vitro intrinsic clearance;
D O I
10.1080/00498250600709778
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
It is important to determine the cytochrome P450 (CYP) contribution of certain drugs by taking into consideration the attrition due to issues such as genetic polymorphism and inter-individual variation. In many cases in the early discovery stage, the metabolites of a new chemical have not been identified. Therefore, the present paper devised an approach in which the in vitro intrinsic clearance (CLint) value for new chemicals was determined by measuring substrate depletion. The following prediction methods were compared to calculate CLint using data from recombinant CYP enzymes: (1) the relative CYP content in human liver microsomes; (2) the relative activity factor (RAF) based on the V-max value; and (3) the RAF value based on the CLint value. The most accurate prediction method was RAF based on CLint. This method would be useful in the early drug-discovery process in cases in which the main metabolite is not identified.
引用
收藏
页码:671 / 683
页数:13
相关论文
共 24 条
[1]
Emoto Chie, 2005, Drug Metab Pharmacokinet, V20, P351, DOI 10.2133/dmpk.20.351
[2]
Emoto Chie, 2003, Drug Metab Pharmacokinet, V18, P287, DOI 10.2133/dmpk.18.287
[3]
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism [J].
Huang, WL ;
Lin, YS ;
McConn, DJ ;
Calamia, JC ;
Totah, RA ;
Isoherranen, N ;
Glodowski, M ;
Thummel, KE .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) :1434-1445
[4]
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population [J].
Kimura, M ;
Ieiri, I ;
Mamiya, K ;
Urae, F ;
Higuchi, S .
THERAPEUTIC DRUG MONITORING, 1998, 20 (03) :243-247
[5]
EXTRAHEPATIC METABOLISM OF DRUGS IN HUMANS [J].
KRISHNA, DR ;
KLOTZ, U .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :144-160
[6]
Characterization of CYP2C19 and CYP2C9 from human liver:: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations [J].
Lasker, JM ;
Wester, MR ;
Aramsombatdee, E ;
Raucy, JL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 353 (01) :16-28
[7]
McGinnity DF, 2000, DRUG METAB DISPOS, V28, P1327
[8]
Nakajima M, 1999, DRUG METAB DISPOS, V27, P1381
[9]
Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor:: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities [J].
Nakajima, M ;
Tane, K ;
Nakamura, S ;
Shimada, N ;
Yamazaki, H ;
Yokoi, T .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :952-963
[10]
INTERETHNIC DIFFERENCES IN GENETIC-POLYMORPHISM OF DEBRISOQUIN AND MEPHENYTOIN HYDROXYLATION BETWEEN JAPANESE AND CAUCASIAN POPULATIONS [J].
NAKAMURA, K ;
GOTO, F ;
RAY, WA ;
MCALLISTER, CB ;
JACQZ, E ;
WILKINSON, GR ;
BRANCH, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (04) :402-408